GE Healthcare is collaborating with the Australian Commonwealth Scientific and Industrial Research Organization (CSIRO) on a research and development project to improve the understanding of the causes and diagnosis of Alzheimer's disease.
GE will provide its F-18 flutemetamol investigational PET imaging agent to the government agency for use in the Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Aging (AIBL), which will seek to discover which biomarkers, cognitive characteristics, and health and lifestyle factors may determine subsequent development of symptomatic Alzheimer's disease, the company said.
